Acute and chronic liver diseases constitute a global concern and the concern is worsened by the lack of reliable liver protective drugs, despite the increasing need for agents to protect the liver from damage. Therefore, complementary and alternative medicines for the treatment of liver diseases have been receiving considerable interest (Seeff et al., 2001) . Therapeutically effective agents from natural products may reduce the risk of clinical toxicity.
INTRODUCTION

Abstract
trichloromethyl radical ( · CCl 3 ), which initiates lipid peroxidation and protein oxidation leading to hepatocellular damage (Manibusan et al., 2007) .
Artemisia capillaris Thunb. (Compositae) is one of the oldest and most commonly prescribed herbs in Eastern traditional medicine, and has been used as an analgesic, antimicrobial agent and a remedy for the treatment of hepatitis and bilious disorders (Chang and But, 1987 ). An aqueous extract of Artemisia capillaris was shown to inhibit interleukin (IL)-1 receptor-and tumor necrosis factor (TNF) receptor-induced cytotoxicity and ethanol-induced apoptosis of HepG2 cells (Koo et al., 2002) . A previous study reported that Artemisia capillaris reduced the lipopolysaccharide-induced infl ammatory response in a human hepatoma cell line and in the rat liver (Hong et al., 2004) , and prevented 2,2'-azobis(2-amidinopropane) dihydrochloride-induced liver damage in rats (Han et Original Article Biomol Ther 20(4) , 406-412 (2012) www.biomolther.org www.biomolther.org kyunkwan University Animal Care Committee Guidelines. The animals were randomly assigned to 6 groups comprising 8-10 animals per group. The mice in group 1 (control) intraperitoneally received only olive oil (10 ml/kg). In groups 2 to 6, CCl 4 dissolved in olive oil (1:499, v/v) was administered intraperitoneally (fi nal concentration of 20 μl/kg). Groups 1 and 2 (vehicle) were treated intraperitoneally with Tween-80 in saline (1:9, v/v). The animals in groups 3 to 5 were treated intraperitoneally with isorhamnetin-3-O-galactoside (50, 100, and 200 mg/kg), and group 6 was intraperitoneally treated with silymarin (positive control, 800 mg/kg), 30 min before and 2 h after CCl 4 injection. The timing of the isorhamnetin-3-O-galactoside treatment was selected based on the previous report (Kim et al., 2010) . Blood was collected 24 h after CCl 4 administration. Each liver was isolated and stored at -75 o C for analysis, except for the left lobe, which was used for histological studies.
Serum aminotransferases activities
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities were determined by standard spectrophotometric procedures using the ChemiLab ALT and AST assay kits (IVDLab Co., Uiwang, Korea), respectively.
Histological analysis
Liver tissues were removed from a portion of the left lobe, and fi xed immediately in 10% neutral buffered formalin, embedded in paraffi n, and then sectioned at 5 μm thickness. Serial sections were stained with hematoxylin and eosin for evaluation of portal infl ammation, hepatocellular necrosis, and infl ammatory cell infi ltration. The sections were examined in a blind manner under an Olympus CKX 41 microscope (Olympus optical Co. Ltd., Tokyo, Japan).
Lipid peroxidation
The steady-state level of malondialdehyde (MDA), which is the end product of lipid peroxidation, was analyzed in liver homogenates by spectrophotometric measurement of the levels of thiobarbituric acid reactive substances at 535 nm, as described by Buege and Aust (1978) , using 1,1,3,3-tetraethoxypropane (Sigma, St. Louis, MO, USA) as the standard.
Serum TNF-α level
Serum concentration of TNF-α was quantifi ed using a commercial TNF-α enzyme-linked immunosorbent assay (ELISA) kit (BD Biosciences Co., CA, USA).
Western blot immunoassay
Freshly isolated liver tissue was homogenized in lysis buffer for the preparation of whole protein extracts. NE-PER ® (Pierce Biotechnology, Rockford, IL, USA) was used for the extraction of nuclear proteins according to the manufacturer's instructions. The BCA Protein Assay kit (Pierce Biotechnology) was used to determine protein concentrations. Protein samples were loaded on 10-15% polyacrylamide gels, separated by sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS/PAGE) and then transferred to PVDF membranes (Millipore, Billerica, MA, USA) using the Semi-Dry Trans-Blot Cell (Bio-Rad Laboratories, Hercules, CA, USA). After the transfer, the membranes were washed with 0.1% Tween-20 in 1×Tris Buffered Saline (TBS/T) and blocked for 1 h at room temperature with 5% (w/v) skim milk powder in TBS/T. The blots were then incubated overnight at 4 o C with primary antibodies. The al., 2006). Isorhamnetin-3-O-galactoside ( Fig. 1) , one of the fl avonoid constituents from Artemisia capillaris, exerted antiinfl ammatory activity by inhibiting the production of 5-lipoxygenase-induced leukotriene (Kwon et al., 2011) . Therefore, this study was designed to investigate the protective effects of isorhamnetin-3-O-galactoside against CCl 4 -induced acute hepatic injury, with particular attention to the oxidative stress and infl ammatory pathways.
MATERIALS AND METHODS
Isolation of isorhamnetin-3-O-galactoside from an Artemisia capillaris
The whole plant of Artemisia capillaris Thunb. was dried and grinded to powder. The dried powder (9.5 kg) was then extracted with hot MeOH (50.0 l×3 times) for 3 h. After fi ltration, total fi ltrate was concentrated to dryness in vacuo at 400 o C to obtain the MeOH extract (900 g). Following this, the MeOH extract was suspended in distilled water:MeOH (9:1) and successively partitioned with dichloromethane (CH 2 Cl 2 ), ethyl acetate (EtOAc), n-butanol (n-BuOH) to yield CH 2 Cl 2 (354 g), EtOAc (141 g), n-BuOH (196 g) fractions, respectively, as well as the H 2 O residue (218 g). n-BuOH fractions were chromatographed over HP-20 diaion using the H 2 O:MeOH; (1:0→6:4→4:6→0:1) solvent system to afford 4 major subfractions H 2 O (132 g), 40% MeOH (30.4 g), 60% MeOH (21 g) and MeOH (6.8 g), respectively. 60% MeOH subfraction was chromatographed in a silica gel column using CH 2 Cl 2 :MeOH (20:1) with a gradual increase in MeOH in order to obtain 17 subfractions (6F-1 to 6F-17). Decantation of subfraction 6F-3 yielded isorhamnetin-3-O-galactoside (270 mg). .4 (C-3'), 146.99 (C-4'), 133.1 (C-3), 121.9 (C-6'), 121.1 (C-1'), 115.1 (C-5'), 113.5 (C-2'), 104.0 (C-10), 101.6 (Gal-1), 98.7 (C-6), 93.7 (C-8), 75.9 (Gal-2), 73.1 (Gal-3), 71.3 (Gal-5), 67.96 (Gal-4), 60.3 (Gal-6), 55.99 (-OCH 3 ).
Treatment of animals
Male ICR mice weighing 25-30 g (Daehan Biolink Co., Eum-seong, Korea) were fasted overnight but given tap water ad libitum. All animals were treated humanely under the Sung- next day, the blots were incubated in appropriate secondary antibodies and were detected using an ECL detection system (iNtRON Biotechnology Co., Ltd., Korea), according to the manufacturer's instructions. ImageQuant TM TL software (Amersham Biosciences/GE Healthcare, Piscataway, NJ, USA) was used for the densitometric evaluation of visualized immuno-reactive bands. Primary antibodies against inducible nitric oxide synthase (iNOS) (Transduction Laboratories, San Jose, CA, USA; 1:1,000 dilution), cyclooxygenase-2 (COX-2) (Cayman, Ann Arbor, MI, USA; 1:1,000 dilution), phoshoprylated (p)-p38, p-c-Jun N-terminal kinase (JNK), total p38, and total JNK (Cell Signaling Technology Inc., Beverly, MA, USA; 1:1,000), p-extracellular signal-regulated kinase (ERK) and total ERK (Cell Signaling Technology Inc.; 1:2,000), nuclear factor (NF)-κB/p65 (Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:1,000) and c-Jun p39 phosphorylated on serine-63 (Santa Cruz Biotechnology; 1:500), heme oxygenase-1 (HO-1) (Stressgen Bioreagents Corp., Ann Arbor, MI, USA; 1:2,500) and fi nally nuclear factor erythroid 2-related factor 2 (Nrf2) (Santa Cruz Biotechnology; 1:1,000) were used and the signals were normalized to that of β-actin (Sigma; 1:2,500 dilution) or lamin B1 (Abcam, Cambridge, UK; 1:2,500).
Total RNA extraction and reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted and the fi rst strand of cDNA was synthesized by reverse transcription of total RNA using oligo(dT) 12-18 primer and SuperScript TM II RNase H-Reverse Transcriptase (Invitrogen Tech-LineTM, Carlsbad, CA, USA). PCR reaction was carried out in a 20 μl reaction volume with a diluted cDNA sample. Final reaction concentrations were as follows: sense and antisense primers, 10 pM; dNTP mix, 250 μM; ×10 PCR buffer, and Ex Taq DNA polymerase, 0.5 U/reaction. PCR was carried out with an initial denaturation step at 94 o C for 5 min, and a fi nal extension step at 72 o C for 7 min in the GeneAmp 2700 thermocycler (Applied Biosystems, Foster City, CA, USA). The primers used in this study are demonstrated in Table 1 o C (60 s) for β-actin. Following RT-PCR, 10 μl samples of the PCR products were visualized by ultraviolet illumination after electrophoresis through 1.5% agarose gel and ethidium bromide staining. The intensity of each PCR product was analyzed semi-quantitatively using a digital camera (DC120, Eastman Kodak, New Haven, CT, USA). Table 1 . PCR primers used in this study and the amplifi ed product length Gene (accession number)
Primer sequences (5`-3`) Product length (bp) 
Statistical analysis
All results are presented as mean ± SEM. The overall signifi cance of the data was examined by one-way analysis of variance. Differences between the groups were considered signifi cant at p<0.05 with the appropriate Bonferroni correction made for multiple comparisons.
RESULTS
Eff ect of isorhamnetin-3-O-galactoside on hepatocellular damage
As shown in Table 2 , serum ALT and AST activities were 40 ± 5 U/l and 32 ± 3 U/l in the control group. The vehicle-treated CCl 4 group showed increases in serum ALT and AST activities at 24 h after CCl 4 injection (13,001 ± 636 U/l and 10,090 ± 730 U/l, respectively). Isorhamnetin-3-O-galactoside at doses of 100 and 200 mg/kg signifi cantly attenuated the increases in ALT activity to 9,501 ± 666 U/l and 9,362 ± 540 U/l, respectively. Consistent with the ALT data, the serum AST levels were signifi cantly attenuated to 6,345 ± 669 U/l and 6,979 ± 755 U/l by 100 and 200 mg/kg of isorhamnetin-3-O-galactoside, respectively. Silymarin at 800 mg/kg also signifi cantly attenuated the increases in ALT and AST activities to 9429 ± 607 U/l and 6,946 ± 765 U/l, respectively. However, 50 mg/kg of isorhamnetin-3-O-galactoside did not affect the serum ALT and AST activities.
The histological features shown in Fig. 2A demonstrate a normal liver lobular architecture and cell structure in the control group. In contrast, hepatocyte ballooning and necrosis were observed in the vehicle-treated CCl 4 group with multiple areas of portal infl ammation as well as a moderate increase in infl ammatory cell infi ltration (Fig. 2B) . These pathological changes were attenuated by 100 mg/kg of isorhamnetin-3-Ogalactoside (Fig. 2C) and 800 mg/kg of silymarin (Fig. 2D ).
Isorhamnetin-3-O-galactoside alone did not affect serum aminotransferase activities (data not shown).
Eff ect of isorhamnetin-3-O-galactoside on lipid peroxidation
In the control group, the level of MDA was 0.5 ± 0.04 nmol/mg protein. Following CCl 4 injection, the level of MDA increased to 3.2 ± 0.5 nmol/mg protein. 100 and 200 mg/kg of isorhamnetin-3-O-galactoside signifi cantly attenuated this increase in the MDA level (1.5 ± 0.1 nmol/mg protein and 1.4 ± 0.1 nmol/mg protein, respectively), while 50 mg/kg of isorhamnetin-3-O-galactoside did not affect the level of MDA (Table 2) .
Eff ect of isorhamnetin-3-O-galactoside on TNF-α, iNOS, COX-2, HO-1 and Nrf2 protein expression
The serum level of TNF-α in the control group was 9.0 ± 2.6 pg/ml. After CCl 4 treatment, the serum level of TNF-α increased to 162.6 ± 17.9 pg/ml and this increase was significantly attenuated (98.3 ± 14.0 pg/ml) by 100 mg/kg of isorhamnetin-3-O-galactoside (Fig. 3) . Compared with the control group, the levels of iNOS, COX-2 and HO-1 protein expression were 2.2-, 1.7-and 1.7-fold higher in the CCl 4 group, respectively. 100 mg/kg of isorhamnetin-3-O-galactoside signifi cantly attenuated the increases in iNOS and COX-2 protein expression levels, while augmenting HO-1 protein expression.
To investigate the mechanism of HO-1 upregulation by isorhamnetin-3-O-galactoside, we assessed the nuclear translocation of Nrf2, a well-established transcription factor that regulates HO-1 expression. At 24 h after CCl 4 injection, the level of nuclear Nrf2 protein expression was increased and 100 mg/ kg of isorhamnetin-3-O-galactoside was found to enhance this increase (Fig. 4) .
Eff ect of isorhamnetin-3-O-galactoside on iNOS, COX-2 and HO-1 mRNA expression
Compared with the control group, the levels of iNOS, COX-2 and HO-1 mRNA expression increased to 1.7-, 1.9-and 1.5-fold in the CCl 4 group, respectively. 100 mg/kg of isorhamnetin-3-O-galactoside signifi cantly attenuated the increase of iNOS mRNA expression, while augmenting HO-1 mRNA expression (Fig. 5) . 
Eff ect of isorhamnetin-3-O-galactoside on phosphorylation of mitogen-activated protein kinases (MAPKs) and nuclear translocation of NF-κB and activating protein (AP)-1
After CCl 4 injection, phosphorylation of JNK, ERK, and p38 increased to 2.6 times, 1.5 times, and 1.4 times the control value, respectively. 100 mg/kg of isorhamnetin-3-O-galactoside attenuated the phosphorylation of JNK, ERK and p38.
Moreover, nuclear levels of p 65, a subunit of NF-κB, and phosphorylated c-Jun (p-c-Jun) showed a marked increase in the CCl 4 group compared with the control group, respectively. Isorhamnetin-3-O-galactoside at 100 mg/kg signifi cantly attenuated these increases (Fig. 6, 7) .
DISCUSSION
CCl 4 -induced hepatic injury is a widely used experimental model for hepatoprotective drug screening. Recently, we screened the 70% ethanol and water extracts of Artemisia capillaris and its active components for hepatoprotective agents. Among them, hyperoside and isorhamnetin-3-O-galactoside were shown to inhibit CCl 4 -induced hepatotoxicity in primary hepatocyte cultures (data not shown). In this study, we investigated the hepatoprotective effects of isorhamnetin-3-Ogalactoside against CCl 4 -induced liver injury in vivo.
In the vehicle-treated CCl 4 group, the ALT and AST activities were dramatically increased, indicating severe hepatocellular damage. In contrast, isorhamnetin-3-O-galactoside markedly decreased the release of ALT and AST. The hepatoprotective effect of isorhamnetin-3-O-galactoside appeared to be similar to that of silymarin, a potent hepatoprotective agent. The histological examination of the liver samples strongly supports the protective effect of isorhamnetin-3-O-galactoside. CCl 4 caused centrizonal necrosis, portal infl ammation, and Kupffer cell hyperplasia. These alterations were signifi cantly attenuated by isorhamnetin-3-O-galactoside. These results suggest that isorhamnetin-3-O-galactoside may be appropriate for clinical applications to treat liver disorders.
CCl 4 is responsible for oxidative stress and lipid peroxida- tion through the CYP2E1-mediated generation of the highly reactive · CCl 3 , leading to eventual cellular damage characterized by hepatocellular necrosis (Taïeb et al., 2005) . In this study, isorhamnetin-3-O-galactoside exhibited protective effects by suppressing CCl 4 -mediated oxidative damage through decreased production of free radical derivatives, as evidenced by the decreased MDA level at doses of 100 mg/kg and 200 mg/kg. Stressors such as excessive oxidative stress readily induce upregulation of HO-1 (Otterbein and Choi, 2000) . HO-1 is an endogenous and cytoprotective enzyme with the main activity catabolizing the oxidative degradation of heme into carbon monoxide (CO), free iron, and biliverdin. Bilirubin/biliverdin is a potent antioxidant that scavenges peroxyradicals, and CO exerts a powerful antiinfl ammatory effect (Ryter et al., 2007) . Several dietary phytochemicals such as glycyrrhizin and hyperoside were shown to induce HO-1 protein and gene expression in our previous studies (Lee et al., 2007; . Nrf2 is a transcription factor that induces expression of various cytoprotective enzymes possessing the antioxidant response element (ARE) in the promoter region and targets genes including glutathione peroxidase, glutathione S-transferase, glutamate cysteine ligase, and HO-1 (Kobayashi and Yamamoto, 2006) . In our study, hepatic Nrf2 and HO-1 protein and gene expression levels were markedly increased after CCl 4 treatment. Furthermore, treatment with isorhamnetin-3-O-galactoside markedly augmented Nrf2 translocation and HO-1 protein and mRNA expression, suggesting that a strong induction of HO-1 via Nrf2 by isorhamnetin-3-O-galactoside protects liver cells from CCl 4 -induced oxidative cellular injuries.
Kupffer cells release a number of proinfl ammatory mediators which are believed to aggravate CCl 4 -induced hepatic injury (Badger et al., 1996) . TNF-α, a proinfl ammatory cytokine, is rapidly produced by macrophages in response to tissue damage (Brouckaert and Fiers, 1996) . DeCicco et al., (1998) have reported the stimulation of TNF-α production in both serum and the liver following CCl 4 administration, and suggested that · CCl 3 activates Kupffer cells to release TNF-α. TNF-α also stimulates the release of cytokines from macrophages and induces the phagocytic oxidative metabolism and NO production (Morio et al., 2001) . Nitric oxide (NO) is produced through the action of iNOS, and is involved in various processes including vasodilation and neurotransmission, and the nonspecifi c host defense system. NO can also react with reactive oxygen species to form cytotoxic oxidants such as peroxynitrite (Ródenas et al., 1995) .
Previous studies reported that the induction of COX in the infl ammatory response is the secondary effect of CCl 4 -induced hepatotoxicity (Basu, 1999) . COX-2 is induced by proinfl ammatory stimuli to form prostaglandins from arachidonic acid (Planagumà et al., 2005) . The results of this study showed a signifi cant increase in the serum TNF-α level and iNOS and COX-2 protein and mRNA expression levels in the liver after CCl 4 administration. These increases were attenuated by treatment with isorhamnetin-3-O-galactoside treatment, suggesting suppression of infl ammatory responses.
The two transcription factors, NF-κB and AP-1, are sensitive to the redox status in abnormal physiological conditions such as CCl 4 -induced acute liver injury (Morio et al., 2001) . NF-κB is an early response transcription factor and the nuclear translocation of NF-κB leads to gene expression of proinfl ammatory cytokines. AP-1 is a dimer consisting of JUN, FOS, ATF and 
